firstwordpharmaJanuary 22, 2019
Tag: Johnson & Johnson , drug sales , Fourth-Quarter , Johnson & Johnson
Headline results for the fourth quarter:
Prescription drug sales |
$10.2 billion (forecasts of $10 billion) |
+5.3% |
Overall revenue |
$20.4 billion (forecasts of $20.2 billion) |
+1% |
Profit |
$3 billion |
Versus loss of $10.7 billion |
Note: All changes are versus the prior-year period unless otherwise stated
What the company said:
CEO Alex Gorsky suggested that the results "can be attributed to accelerated underlying sales performance across each of our businesses, where we also leveraged our scale across the enterprise to improve margins."
Other results:
What analysts said:
Credit Suisse analyst Vamil Divan noted that Johnson & Johnson's quarterly profit was boosted by from an effective tax rate of 2.6 percent, amounting to just $80 million. Meanwhile, J.P. Morgan analyst Chris Schott said the positive outlook for the company's pharmaceutical division was tempered by ongoing growth challenges to its medical device unit and ongoing litigation, which saw legal costs double to $1.3 billion.
Looking ahead:
Johnson & Johnson expects sales of between $80.4 billion and $81.2 billion this year, versus $81.6 billion in 2018. Meanwhile, earnings per share are forecast to be in the range of $8.50 to $8.65, reflecting growth of between 5.7 percent and 7.6 percent. Analysts predict full-year sales in 2019 of around $82.3 billion, on earnings of $8.60 per share.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: